Literature DB >> 12409994

Delta opioid antagonist effects of buprenorphine in rhesus monkeys.

S S Negus1, J M Bidlack, N K Mello, M S Furness, K C Rice, M R Brandt.   

Abstract

Buprenorphine is an opioid with high affinity for delta, mu and kappa opioid receptors. The delta receptor-mediated effects of buprenorphine have not been studied. Thus, the present study examined the delta receptor-mediated effects of buprenorphine in rhesus monkeys. assays of receptor binding and agonist-stimulated GTP S binding confirmed that buprenorphine had high affinity for, and low efficacy at, delta receptors. In an assay of schedule-controlled responding for food presentation in four monkeys, buprenorphine produced little effect alone, but it antagonized the effects of the delta agonist SNC80, the mu agonist morphine and the kappa agonist U50,488. Buprenorphine was approximately 30-fold less potent as a delta antagonist than as a mu or kappa antagonist. In three monkeys trained to discriminate SNC80 from saline, buprenorphine alone produced only saline-appropriate responding, and buprenorphine pretreatment antagonized the discriminative stimulus effects of SNC80. In a fourth monkey, buprenorphine produced a partial substitution for SNC80 that could be blocked by the delta-selective antagonist naltrindole but not by the mu-selective antagonist quadazocine. These results indicate that, in rhesus monkeys, buprenorphine has very low efficacy at delta receptors, and that buprenorphine produces delta receptor-mediated effects with lower potency than it produces mu or kappa receptor-mediated effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409994     DOI: 10.1097/00008877-200211000-00005

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  23 in total

Review 1.  Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Opioid receptors and signaling on cells from the immune system.

Authors:  Jean M Bidlack; Maxim Khimich; Amy L Parkhill; Sarah Sumagin; Baoyong Sun; Christopher M Tipton
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-08       Impact factor: 4.147

3.  Sex differences in the effectiveness of buprenorphine to decrease rates of responding in rhesus monkeys.

Authors:  Kathryn L Schwienteck; S Stevens Negus; Matthew L Banks
Journal:  Behav Pharmacol       Date:  2019-06       Impact factor: 2.293

4.  Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys.

Authors:  Shawn M Flynn; Phillip M Epperly; April T Davenport; Gerta Cami-Kobeci; Stephen M Husbands; Mei-Chuan Ko; Paul W Czoty
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

Review 5.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 6.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

7.  Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons.

Authors:  G Cristina Brailoiu; Elena Deliu; Robert Hooper; Nae J Dun; Ashiwel S Undieh; Martin W Adler; Khalid Benamar; Eugen Brailoiu
Journal:  Drug Alcohol Depend       Date:  2011-12-21       Impact factor: 4.492

8.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

9.  An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.

Authors:  Richard C Crist; Toni-Kim Clarke; Alfonso Ang; Lisa M Ambrose-Lanci; Falk W Lohoff; Andrew J Saxon; Walter Ling; Maureen P Hillhouse; R Douglas Bruce; George Woody; Wade H Berrettini
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

10.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.